1Shibuya K,Mathers CD,Boschi-Pinto C,et al.Global and regional estimates of cancer mortality and incidence by site:Ⅱ.Results for the global burden of disease 2000[J].BMC Cancer,2002,2(1):37.
2Eiben GL,Velders MP,Schreiber H,et al.Establishment of all HLA-A0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A0201 transgenie mice[J].Cancer Res,2002,62(20):5792-5799.
3Man C.Efficacy of human papillomavims-16 vaccine to prevent cervical intraepithelial neoplasia:a randomized controlled trial[J].Ohstet Gynecol,2006,107:18-27.
4Slomovitz BM,Sun CC,Frumovitz M,et al.Are women ready for the cervical cancer vaccine?[J].Gynecol Oncol,2005,96:912a
5Stevenson FK,Roseaberg W.DNA vaccination:a potential weapon against infection and cancer[J].Vox Sang,2001,80(1):12-18.
6Hanke T,McMichael AJ,Samuel RV,et al.Lack of toxicity and persistence in the mouse associated with administration of candidate DNA and modified vaccinia virus Ankara(MVA)-based HIV vaccines for Kenyu[J].Vaccine,2002,21:108-114.
7Hauser H,Shen L,Gu QL,et al.Secretory heat-shock protein as a dendritic cell-targeting molecule:a new strategy to enhance the potency of genetic vaccines[J].Gene Ther,2004,11(11):924-932.
8Kaufmann AM,Stem PL,Rankin EM,et al.Safety and immunogenicity of TA-HPV.a recombinant vaccinia virus expressing modified human papillomavims(HPV)-16 and HPV-18 E6 and E7 genes,in women with progressive carvical cancer[J].Clin Cancer Res,2002,8(12):3676-3685.
9Le Buanec H,Cohen L,Paturance S,et al.Therapeutic vaccine to control stromal tumor-induced immunosuppression in human uterine cervix cancer[J].Cell Mol Biol(Noisy-le-grand),2003,49(4):667-671.
10Zwaveling S.Ferreira MSC,Nouta J,et al.Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides[J].Immunoloy,2002,169:350-358.
